Comparative Pharmacology
Head-to-head clinical analysis: BRETHAIRE versus SEREVENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRETHAIRE versus SEREVENT.
BRETHAIRE vs SEREVENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Selective long-acting beta2-adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
2 inhalations (370 mcg each) by oral inhalation 4 times daily as needed; maximum 12 inhalations per day.
50 mcg (2 inhalations) twice daily via inhalation; maximum 100 mcg/day.
None Documented
None Documented
3.8 hours (terminal elimination half-life; clinical context: dosing interval typically every 4-6 hours)
Terminal elimination half-life of 5.5 hours (range 3–7 hours). No dose adjustment in renal or hepatic impairment; accumulation can occur in severe hepatic disease, monitor.
Renal (25% unchanged, 75% as inactive sulfate conjugates), biliary/fecal (minimal)
Primarily hepatic metabolism via CYP3A4; ~60% excreted in feces as parent drug and metabolites; ~25% in urine as metabolites; negligible (0.5%) unchanged drug in urine.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist